Patient Characteristics, Microbiology, and Mortality of Infective Endocarditis After Transcatheter Aortic Valve Implantation

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Dokumenter

  • Fulltext

    Forlagets udgivne version, 692 KB, PDF-dokument

Background
Infective endocarditis (IE) after transcatheter aortic valve implantation (TAVI) is associated with high mortality and surgery is rarely performed. Thus, to inform on preventive measures and treatment strategies, we investigated patient characteristics and microbiology of IE after TAVI.

Methods
Using Danish nationwide registries, we identified patients with IE after TAVI, IE after non-TAVI prosthetic valve (nTPV), and native valve IE. Patient characteristics; overall, early (≤12 m), and late IE (>12 m) microbiology; and unadjusted and adjusted mortality were compared.

Results
We identified 273, 1022, and 5376 cases of IE after TAVI, IE after nTPV, and native valve IE. Age and frailty were highest among TAVI IE (4.8%; median age: 82 y; 61.9% frail). Enterococcus spp. were common for IE after TAVI (27.1%) and IE after nTPV (21.2%) compared with native valve IE (11.4%). Blood culture–negative IE was rare in IE after TAVI (5.5%) compared with IE after nTPV (15.2%) and native valve IE (13.5%). The unadjusted 90-day mortality was comparable, but the 5-year mortality was highest for IE after TAVI (75.2% vs 57.2% vs 53.6%). In Cox models adjusted for patient characteristics and bacterial etiology for 1–90 days and 91–365 days, there was no significant difference in mortality rates.

Conclusions
Patients with IE after TAVI are older and frailer, enterococci and streptococci are often the etiologic agents, and are rarely blood culture negative compared with other IE patients. Future studies regarding antibiotic prophylaxis strategies covering enterococci should be considered in this setting.
OriginalsprogEngelsk
TidsskriftClinical Infectious Diseases
Vol/bind77
Udgave nummer12
Sider (fra-til)1617-1625
Antal sider9
ISSN1058-4838
DOI
StatusUdgivet - 2023

Bibliografisk note

Funding Information:
Potential conflicts of interest. L. K.: Lecture fees from AstraZeneca, Bayer, Boehringer, Novartis, and Novo. H. B.: Lecture fees from Amgen, MSD, Bristol-Myers Squibb, and Sanofi. M. V.: Lecture fees from MyLab Oy. J. B. O.: Speaker’s honoraria or consultancy fees from Bayer, Bristol-Myers Squibb, and Pfizer. E. L. F.: Independent research grant from Novo Nordisk Foundation. All other authors report no potential conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

Publisher Copyright:
© The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America.

ID: 377812684